Eton Pharmaceuticals, Inc.
NASDAQ:ETONBiotechnology
-$0.46 today
- Market cap
- $1.79B
- Beta
- 0.89
- P/E (TTM)
- -597.6
- EPS (TTM)
- -$0.05
Volume 0.48M
Average 0.43M
ETON Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Eton Pharmaceuticals, Inc.NASDAQ: ETON
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow growth accelerates
Q1 FY2026 financing cash flow of $1.39M rose 252.5% year over year, ahead of the -94.6% change in trailing-twelve-month financing cash flow. Sequentially, it rose 229.9% from the prior quarter.
Context
- Financing cash flow amounted to 1.0% of revenue in FY2025, down 82.5 pp from a year earlier.
- Financing cash flow increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +252.5% holds above the trailing-twelve-month pace of -94.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 815K USD
- Year-over-year change
- -97.5%
- 4-year CAGR
- +20.2%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 815K | -97.5% |
| FY2024 | 2024-12-31 | 32.59M | +3505.7% |
| FY2023 | 2023-12-31 | (957K) | -614.2% |
| FY2022 | 2022-12-31 | (134K) | -134.3% |
| FY2021 | 2021-12-31 | 391K | — |
Financing Cash Flow vs competitors
How ETON compares with its peers on the latest reported figures
- ETON's LTM Mar 2026 financing cash flow of $1.81M is the smallest of the 10 companies compared; the peer median is $44.68M.
- Its year-over-year change of -94.6% is the 9th highest of 10, against a peer median of +269.7%.
- Financing cash flow amounts to 2.1% of revenue for ETON, versus a peer median of 37.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $477.84M | +19.6% | -1.6% | 71.4% | |
| LTM Sep 2026 | $261.93M | +546.0% | — | 27.3% | |
| LTM Sep 2026 | $245.69M | +211.1% | — | 37.7% | |
| LTM Mar 2026 | $173.2M | +64727.2% | -4.7% | — | |
| LTM Mar 2026 | $44.68M | +269.7% | — | — | |
| LTM Mar 2026 | $42.35M | -151.3% | +13.0% | 34.6% | |
| LTM Mar 2026 | $40.83M | +2642.3% | — | 58.6% | |
| LTM Mar 2026 | $23.28M | +292.0% | +3.0% | 45.6% | |
| LTM Mar 2026 | $3.53M | +109.1% | — | 1.0% | |
| LTM Mar 2026 | $1.81M | -94.6% | — | 2.1% | |
| Peer median (excluding ETON) | $44.68M | +269.7% | +0.7% | 37.7% | |
Competitors are the stored peer set for ETON. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (1.96M) | (9.02M) | (936K) | (3.82M) | (4.6M) |
| Depreciation & Amortization | 462K | 1.77M | 901K | 1.15M | 4.04M |
| Deferred Income Tax | (546K) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 3.38M | 4.22M | 3.14M | 3.17M | 5.51M |
| Change in Working Capital | (6.21M) | 7.66M | 3.53M | (698K) | (859K) |
| Accounts Receivables | (5.42M) | 3.62M | (1.56M) | (3.12M) | (6.4M) |
| Inventory | 692K | (7K) | (354K) | (1.31M) | (5.88M) |
| Accounts Payables | (570K) | (8K) | 53K | 2.32M | 6.81M |
| Other Working Capital | (910K) | 4.06M | 5.39M | 1.41M | 4.61M |
| Other Non-Cash Items | 148K | 189K | 184K | 1.18M | 6.43M |
| Operating Cash Flow | (4.72M) | 4.82M | 6.82M | 969K | 10.52M |
| Capital Expenditures | (3.26M) | (2.79M) | (775K) | (26K) | (333K) |
| Acquisitions (Net) | 700K | 0 | 0 | (30M) | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | (2.75M) | 0 | (9.99M) | 0 |
| Investing Cash Flow | (2.56M) | (2.79M) | (775K) | (40.01M) | (333K) |
| Debt Repayment | (150K) | (385K) | (1.16M) | 24.15M | 0 |
| Common Stock Issued | 541K | 0 | 0 | 8.19M | 598K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 251K | 198K | 248K | 217K |
| Financing Cash Flow | 391K | (134K) | (957K) | 32.59M | 815K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (6.89M) | 1.9M | 5.08M | (6.45M) | 11.01M |
| Free Cash Flow | (7.98M) | 2.03M | 6.04M | 943K | 10.19M |
Eton Pharmaceuticals, Inc.
NASDAQ:ETON
Intrinsic Alpha fair value
Locked
Current Price
$61.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.